Joshua Osowicki

Joshua Osowicki

Auto-generated profile, based on publicly available information

Joshua Osowicki

Murdoch Children's Research Institute

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in The Lancet Microbe
Verified
Journal Article
Open access
JOJoshua Osowicki
Joshua Osowicki
KAKristy I Azzopardi
Kristy I Azzopardi
LFLoraine Fabri
Loraine Fabri
HFHannah R Frost
Hannah R Frost
TRTania Rivera-Hernandez
Tania Rivera-Hernandez
ASAndrew C Steer
Andrew C Steer
Streptococcus pyogenes is a leading cause of infection-related morbidity and mortality. A reinvigorated vaccine development effort calls for new clinically relevant human S pyogenes experimental infection models to support proof of concept evaluation of candidate vaccines. We describe the initial Controlled Human Infection for Vaccination Against S pyogenes (CHIVAS-M75) study, in which we aimed to identify a dose of emm75 S pyogenes that causes acute pharyngitis in at least 60% of volunteers when applied to the pharynx by swab. This observational, dose-finding study was done in a clinical trials facility in Melbourne (VIC, Australia). Groups of healthy volunteers aged 18-40 years, at low risk of complicated S pyogenes disease, and without high type-specific anti-emm75 IgG antibodies against the challenge strain were challenged and closely monitored as inpatients for up to 6 days, and then as outpatients for 6 months. Antibiotics were started upon diagnosis (clinical signs and symptoms of pharyngitis and a positive rapid molecular test) or after 5 days in those without pharyngitis. Rapid test results were confirmed by standard bacterial culture. After a sentinel participant, cohorts of five and then ten participants were challenged, with protocol-directed dose-escalation or de-escalation for subsequent cohorts. The primary outcome was the proportion of participants at each dose level with pharyngitis by day 5 after challenge. The study is registered with ClinicalTrials.gov, NCT03361163. Between July 10, 2018, and Sept 23, 2019, 25 healthy adults were challenged with emm75 S pyogenes and included in analyses. Pharyngitis was diagnosed in 17 (85%; 95% CI 62-97) of 20 participants at the starting dose level (1-3 × 105 colony-forming units [CFU]/mL). This high proportion prompted dose de-escalation. At the lower dose level (1-3 × 104 CFU/mL), pharyngitis was diagnosed in one of five participants. Immunological, biochemical, and microbiological results supported the clinical picture, with acute symptomatic pharyngitis characterised by pharyngeal colonisation by S pyogenes accompanied by significantly elevated C-reactive protein and inflammatory cytokines (eg, interferon-γ and interleukin-6), and modest serological responses to streptolysin O and deoxyribonuclease B. There were no severe (grade 3) or serious adverse events related to challenge. We have established a reliable pharyngitis human infection model with reassuring early safety findings to accelerate development of vaccines and other interventions to control disease due to S pyogenes. Australian National Health and Medical Research Council.

1 June 2017 in Journal of Infection
Verified
Journal Article
Closed access
JOJoshua Osowicki
Joshua Osowicki
SKSarah Kapur
Sarah Kapur
LPLinny Kimly Phuong
Linny Kimly Phuong
SDSimon Dobson
Simon Dobson

9 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JAJeremy Anderson
Jeremy Anderson
SISamira Imran
Samira Imran
HFHannah R. Frost
Hannah R. Frost
KAKristy I. Azzopardi
Kristy I. Azzopardi
SJSedigheh Jalali
Sedigheh Jalali
DPDaniel G. Pellicci
Daniel G. Pellicci
Streptococcus pyogenescauses at least 750 million infections and more than 500,000 deaths each year. No vaccine is currently available forS. pyogenesand the use of human challenge models offer unique and exciting opportunities to interrogate the immune response to infectious diseases. Here, we use high-dimensional flow cytometric analysis and multiplex cytokine and chemokine assays to study serial blood and saliva samples collected during the early immune response in human participants following challenge withS. pyogenes. We find an immune signature of experimental human pharyngitis characterised by: 1) elevation of serum IL-1Ra, IL-6, IFN-γ, IP-10 and IL-18; 2) increases in peripheral blood innate dendritic cell and monocyte populations; 3) reduced circulation of B cells and CD4+ T cell subsets (Th1, Th17, Treg, TFH) during the acute phase; and 4) activation of unconventional T cell subsets, γδTCR + Vδ2+ T cells and MAIT cells. These findings demonstrate thatS. pyogenesinfection generates a robust early immune response, which may be important for host protection. Together, these data will help advance research to establish correlates of immune protection and focus the evaluation of vaccines.

1 June 2019 in Vaccine
Verified
Journal Article
Closed access
JOJoshua Osowicki
Joshua Osowicki
KAKristy I. Azzopardi
Kristy I. Azzopardi
CBCiara Baker
Ciara Baker
CWClaire S. Waddington
Claire S. Waddington
MPManisha Pandey
Manisha Pandey
ASAndrew C. Steer
Andrew C. Steer

27 February 2019 in mSphere
Verified
Journal Article
Open access
PDF file
JOJoshua Osowicki
Joshua Osowicki
KAKristy I. Azzopardi
Kristy I. Azzopardi
LMLiam McIntyre
Liam McIntyre
TRTania Rivera-Hernandez
Tania Rivera-Hernandez
COCheryl-lynn Ong
Cheryl-lynn Ong
ASAndrew C. Steer
Andrew C. Steer
GAS ( Streptococcus pyogenes ) is a leading global cause of infection-related morbidity and mortality. A modern CHIM of GAS pharyngitis could help to accelerate vaccine development and drive pathogenesis research. Challenge strain selection is critical to the safety and success of any CHIM and especially so for an organism such as GAS, with its wide strain diversity and potential to cause severe life-threatening acute infections (e.g., toxic shock syndrome and necrotizing fasciitis) and postinfectious complications (e.g., acute rheumatic fever, rheumatic heart disease, and acute poststreptococcal glomerulonephritis). In this paper, we outline the rationale for selecting an emm 75 strain for initial use in a GAS pharyngitis CHIM in healthy adult volunteers, drawing on the findings of a broad characterization effort spanning molecular epidemiology, in vitro assays, whole-genome sequencing, and animal model studies.

24 November 2014 in Medical Journal of Australia
Verified
Journal Article
Closed access
JOJoshua Osowicki
Joshua Osowicki
AGAmanda Gwee
Amanda Gwee
JNJesuina Noronha
Jesuina Noronha
PPPamela Palasanthiran
Pamela Palasanthiran
BMBrendan McMullan
Brendan McMullan
PBPenelope A Bryant
Penelope A Bryant
Perioperative prophylaxis is one area in which there is capacity for improving the quality of prescribing